About Raziel Therapeutics

Raziel Therapeutics is advancing the science of fat removal treatments by harnessing the body’s natural healing mechanism. Backed by leading investors, we build on science developed at the Hebrew University in Jerusalem. Raziel is currently running several clinical studies for diverse fat disorder indications as well as for aesthetics.

Management Team

Alon Bloomenfeld

Alon served in management and board member positions for many public and private companies. Prior to founding Raziel, he was CFO of Collplant (NASDAQ: CLGN), Biomedix Incubator Ltd. (TASE:BMDX), BrightCom Technologies (acquired by NYSE-traded Flextronics), and financial manager at Libit Signal Processing (acquired by Texas Instruments, NYSE:TXN). Alon holds an MBA and a BA in Accounting and Finance.

Eran Blaugrund, Ph.D.

Eran has twenty-five years of drug development experience. He headed the CNS/Pain project leadership group at Teva Pharmaceuticals with accountability for global development and post-approval project activities. Before that, he led pharmacology development of Azilect for treatment of Parkinson’s disease from early development stages to European approval.

Racheli Gueta, Ph.D.

Clinical Development Director
Racheli has a decade of experience in clinical and R&D activities in multi-disciplinary projects in the pharmaceutical and medical device industry. She holds a Ph.D. in structural biology from the Weizmann Institute of Science, Israel

Sharon Cohen Vered, Ph.D.

Sharon has over twenty-five years of experience leading drug development (CMC) teams in pharma, both in large multinationals and in startups. Prior roles includes VP CMC at NeuroDerm, CMC at Orasis Pharmaceuticals, and Head of Parenteral Dosage Forms at Teva innovative R&D. She holds a Ph.D. from Tel Aviv University.

Board of Directors

Dr. Schaison is a CEO, Global President and Chief Commercial Officer in consumer healthcare, consumer goods, and retail sectors (Asia, South America and Europe). His experience includes running a $2.5B+ business at Allergan, acquiring and integrating  a $2B+ organization, and leading global organizations to implement successful operations and drive profitability. Hired by the Chairman and board of directors of Syneron-Candela (Irvine, CA), to take a publically traded company (ELOS) private, Dr. Schaison sold the company to private equity firm Apax in July 2017 for $11/share.

Before joining Allergan, Dr. Schaison served as President, WW Travel Retail & Regional President, LATAM and MEA, at Clarins in New York (2010 – 2013). From 2003 to 2008, Dr. Schaison served as Vice President of Global Skin Care for Johnson & Johnson, with P&L responsibility for Aveeno, Clean & Clear, Lubriderm, and Ambi in international markets. Prior to joining Johnson & Johnson, Dr. Schaison worked in executive positions at L’Oréal (1997 – 2003).

He is a board member of the Galien Foundation, NY, a board member of Sientra (NSQ SIEN), Soltego, and board member of Sente bio-pharmaceutical. Dr. Schiason earned an MBA (Marketing) from the Hautes Études Commerciales (H.E.C.) in Paris, and a doctorate in Pharmacy (Industrial) from the University of Paris V. A dual US and French citizen, and a co-world champion of 1000x100m freestyle swimming relay, he enjoys competitive skiing, scuba diving, and paragliding, and has a Black Belt-Second Dan in Tae Kwon Do. He is also a commercial single and multi-engine pilot.

Mr. Kariv is the co-founder and Chief Executive Officer of Pontifax. He serves as an active board member of many of the fund’s portfolio companies, assuming a special responsibility for strategic planning. Among other positions, Mr. Kariv serves as a board member at Eloxx Pharmaceuticals, LogicBio Therapeutics, Cathworks, and V-Wave. During the 10 years prior to establishing Pontifax, he held senior management positions at top Israeli financial institutions, playing a key role in investing in, nurturing, and managing technology-driven startups. Tomer Kariv holds a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.

Dr. Cabilly holds a PhD in Immunology and is an investor and board member of several companies. He spent four years in the US as a postdoctoral fellow, heading a joint project of the City of Hope Research Institute and Genentech, where he developed a new technology for recombinant antibody production. This invention has secured world patents issued in the US in 1989 and 2001. Today there are 20 drugs in the market based on this technology, including Herceptin, Rituxan, Traceba, Raptiva, and Xolair. Dr. Cabilly also cofounded and was a chief scientist of Ethrog Biotechnology (later sold to Invitrogen), where he invented two dry-buffer technologies.

Mr. Goldin has over 15 years of experience in the life science, industrial and hi-tech industries in the areas of investments, business strategy, deal structure and company management. For the last 10 years Mr. Goldin has served as a vice president at Docor International BV, and has played a key role in investing, managing and nurturing technology-driven companies and startups in the information technology, industrial and life science industries. Until 2010, Mr. Goldin was the CEO of Softlib, an information technology company. Previously, Mr. Goldin was VP of Investments and Analysis at Inventech Venture Capital (TASE: IVTC), where he took an active role in building startup companies and was involved in public offerings, M&A and all aspects of the capital market. Mr. Goldin practiced law in the law office of Israeli, Blustein, Kogan & Co. In addition, he was part of the teaching staff of the MBA program run jointly by Tel Aviv University and Northwestern University's Kellogg School of Management (Chicago, USA). Mr. Goldin participated in the International Marketing and Global Consulting Program, a joint project of the University of Pennsylvania's Wharton Business School and Tel Aviv University's Business School. Mr. Goldin is an associate of the Israel Bar Association. He holds B.A. and M.A degrees in economics, summa cum laude, and an LL.B in law - all from Tel Aviv University.

Dr. Avnur is the Chief Scientific Officer at Quark Venture Inc., a venture investment fund focused on life sciences investments. Prior to Quark, Dr. Avnur was the Global Head of Academic Innovation for Roche Partnering, responsible for creating relationships with the world’s leading academic institutions and world-class innovators, gaining early access to innovation. In that role, she created nine startup companies. Preceding her academic innovation leadership role, Dr. Avnur was based in Basel, Switzerland, working in both diagnostics and pharmaceutical research, progressing from scientist and manager to assuming global responsibilities. At Roche, she contributed to the PHC (Personalized Health Care) initiative and oversaw the advancement of a number of compounds from the bench to clinical studies characterizing the pharmacodynamics and clinical effects. Dr. Avnur was named Distinguished Scientist, the highest scientific appointment at Roche, holds a post-doctorate (Cancer Biology) from Stanford University, and a Ph.D. from Weizmann Institute (Cell Biology).

Mr. Shamir served for 25 years as a pilot and an engineer in the Israeli Air Force. He served as Israel’s Minister of Agriculture and Rural Development and as a member of the Israeli government and its Parliament. Mr. Shamir also served as the chairman of four government companies: EL AL, IAI, National Road Company of Israel, and Metropolitan Mass Transit System, of which he is currently the Chairman. Mr. Shamir has served as a board director and Chairman of many private and listed companies in Israel and abroad, past and present. He has also sat on and led boards as the Chairman for many public institutions, including the Technion, Ben Gurion University, The Shalem Academic Center, Mikve Israel, Ohalo College and many others.

Mr. Lifschitz is General Partner and co-founder of Peregrine Ventures. On behalf of the Fund, Mr. Lifschitz serves on the boards of many of the portfolio companies, including Valtech Cardio, NLT Spine, and CardioNova. Prior to founding Peregrine Ventures, Mr. Lifschitz co-founded and led the business development efforts of a number of medical technology companies including PharmaSys (acquired by Elan Corp. NYSE:ELN), ECR (acquired by AVX Corp. NYSE:AVX), Visioncare Ophthalmic Technologies, and BioControl Ltd. From 2003 to 2007, Mr. Lifschitz also served as a Director of Given Imaging (NASDAQ: GIVN).

Mr. Bloomenfeld is CEO and founder of Raziel Therapeutics. He served in management positions and as a board member for many public and private companies in healthcare, the high-tech industry. Prior to founding Raziel, Mr. Bloomenfeld served as the CFO of Collplant (NASDAQ: CLGN), Biomedix Incubator Ltd. (TASE:BMDX), and BrightCom Technologies (acquired by NYSE-traded Flextronics). He also served as financial manager at Libit Signal Processing, which was acquired by Texas Instruments (NYSE:TXN). Mr. Bloomenfeld holds an MBA from Manchester University and a Bachelor of Arts in Accounting and Finance from Tel Aviv Management Colle